Acute Haemodynamic and Perceptual Responses to Graded Intradialytic Exercise in Patients on Maintenance Haemodialysis: A Randomised Crossover Trial.

J Ren CareSep 1, 2026
Clinical ResearchNephrology

Montaha Hmida, Mohamed Amine Abouzida, Yasmine Bardiaa et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomised crossover trial investigated the acute haemodynamic and perceptual responses to graded intradialytic resistance exercise in 48 stable adults undergoing maintenance haemodialysis. The study found that higher perceived exercise intensity significantly increased systolic blood pressure by 14.9 mmHg and heart rate by 15.5 beats per minute compared to a non-exercise control condition.

Key findings

  • Systolic blood pressure increased by 14.9 mmHg with higher perceived intensity compared to control.
  • Diastolic blood pressure rose by 8.4 mmHg during higher intensity exercise.
  • Heart rate increased by 15.5 beats per minute with higher perceived intensity.
  • Rating of perceived exertion increased by 6.7 points during graded exercise.

Why it matters

Understanding the acute responses to intradialytic exercise can help clinicians tailor exercise prescriptions for patients on haemodialysis, potentially improving their overall health and well-being during treatment.

Source

PubMed · PMID 42703894

Published in J Ren Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.